I agree that this site is using cookies. You can find further informations here.
X
Veillon, R.
182  results:
Search for persons X
?
1

7P Patient-relevant endpoints from PAPILLON: Amivantamab pl..:

Paz-Ares, L. ; Veillon, R. ; Majem, M....
ESMO Open.  9 (2024)  - p. 102586 , 2024
Link: https://doi.org/10.1016/..
 
?
2

34P Treatment sequencing in the VISION study of tepotinib i..:

Griesinger, F. ; Garassino, M.C. ; Felip, E....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S60-S61 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Retraitement par inhibiteurs de points de contrôles immunit..:

Ladouceur, A. ; Barnetche, T. ; Mouterde, G....
Revue du Rhumatisme.  90 (2023)  - p. A290-A291 , 2023
Link: https://doi.org/10.1016/..
 
?
4

PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) S..:

Garassino, M.C. ; Thomas, M. ; Felip, E....
Journal of Thoracic Oncology.  18 (2023)  3 - p. e7-e8 , 2023
Link: https://doi.org/10.1016/..
 
?
5

13MO Safety and efficacy of tusamitamab ravtansine in combi..:

Isambert, N. ; Nagy, T. ; Ravoire, M....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S46-S47 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Real-world multicentre cohort of first-line pembrolizumab a..:

Pons-Tostivint, E. ; Hulo, P. ; Guardiolle, V....
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1881-1890 , 2023
Link: https://doi.org/10.1007/..
 
?
7

Correction to: Real-world multicentre cohort of first-line ..:

Pons-Tostivint, E. ; Hulo, P. ; Guardiolle, V....
Cancer Immunology, Immunotherapy.  72 (2023)  6 - p. 1891-1892 , 2023
Link: https://doi.org/10.1007/..
 
?
8

Intracranial Activity of Tepotinib in Patients (pts) With M..:

Bestvina, C.M. ; Patel, J.D. ; Le, X....
International Journal of Radiation Oncology*Biology*Physics.  112 (2022)  2 - p. e14-e15 , 2022
Link: https://doi.org/10.1016/..
 
?
9

OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Sk..:

Thomas, M. ; Garassino, M. ; Felip, E....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S9-S10 , 2022
Link: https://doi.org/10.1016/..
 
?
10

METex14 ctDNA Dynamics & Resistance Mechanisms Detected in ..:

Paik, P. ; O'Hara, R. ; Veillon, R....
International Journal of Radiation Oncology*Biology*Physics.  112 (2022)  2 - p. e13-e14 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Evolution of bone metastases in patients receiving at least..:

Gefard-Gontier, E. ; Markich, R. ; Zysman, M....
Cancer Immunology, Immunotherapy.  71 (2022)  11 - p. 2609-2618 , 2022
Link: https://doi.org/10.1007/..
 
?
12

Évolution des métastases osseuses chez les patients traités..:

Gefard-Gontier, E. ; Markich, R. ; Prey, S....
Revue du Rhumatisme.  88 (2021)  - p. A67 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Immune checkpoint inhibitors versus second line chemotherap..:

Lefebvre, C. ; Martin, E. ; Hendriks, L.E.L....
Respiratory Medicine and Research.  78 (2020)  - p. 100788 , 2020
Link: https://doi.org/10.1016/..
 
?
14

Intérêt du dépistage et évolution des dysthyroïdies induite..:

Poupon, P. ; Prey, S. ; Gerard, E....
Annales d'Endocrinologie.  79 (2018)  4 - p. 227 , 2018
Link: https://doi.org/10.1016/..
 
?
15

Efficacité et tolérance du crizotinib (xalkori®) dans le ca..:

Girault, C. ; Mosnier-Thoumas, S. ; Veillon, R...
Le Pharmacien Hospitalier et Clinicien.  49 (2014)  2 - p. e69-e70 , 2014
Link: https://doi.org/10.1016/..
 
1-15